Introduction
Non-invasive ventilation (NIV) is an effective evidencebased inter vention for patients with persistent respiratory acidosis during acute exacerbations of chronic obstructive pulmonary disease (COPD). Several systematic reviews have shown that NIV reduce the rate of endotracheal intubation (ETI), length of stay in the intensive care unit (ICU), length of hospital stay as well as mortality. 1, 2 However, outside the realm of randomised-controlled trials (RCT), mortality from acute respiratory failure due to COPD in the clinical setting remains substantial at 10-30%. [3] [4] [5] [6] Optimal setting and timing can potentially maximise the benefits of NIV. 7, 8 Traditionally, NIV is instituted in the ICUs which are highly specialised for intensive monitoring and prompt provision of ETI if patients deteriorate. However, for patients in the emergency department (ED), this entails an additional step of transfer to the ICU which causes delay in commencing NIV. It has been suggested that early use of NIV may provide an opportunity for a successful start before the disease progresses further. 9 This early start can potentially occur outside the ICU in the care of a skilled team. In contrast to the ICU, early NIV in the ED not only reduces delay but also avoids the added risks of transferring unstable patients to another site. 10 Our hospital's medical ICU started using NIV for patients with COPD and other conditions in the middle of the year 2000; we have previously reported some of the outcomes of these patients. 11 In 2003, we received additional funding under the Ministry of Health's Health Services Development Program for COPD management, which we used to purchase an additional non-invasive ventilator for our ED. We hypothesised that a good NIV program, consisting of adequate staff training and well drawn-up protocols for patient selection, could be successfully implemented. The aim of our study was to describe the experience of implementing a NIV program in the ED for patients with severe exacerbations of COPD.
Methods
This was a pre-and post-implementation of protocol study as a historical comparison conducted from 1st January 2001 to 31st December 2009. The post implementation phase commenced on 1st July 2003. Our 950-bed tertiary university hospital has an average ED attendance of 100,000 patients per year. During the period of study, an average 400 COPD patients attended the ED each year. This study was approved by our university hospital's institutional review board with a waiver of consent.
Patients
Both the ICU and the ED kept a registry of patients who received NIV in the respective locations. We included patients, originated from the ED, who were given NIV for COPD exacerbations with acute hypercapnic respiratory failure. The inclusion criteria were both: 1) breathlessness or use of accessory neck muscles or respiratory rate of more than 24 breaths per minute; and 2) arterial blood gas (ABG) showing pH <7.35 and partial pressure of arterial carbon dioxide (PaCO 2 ) >45 mmHg. We excluded patients with h a e m o d y n a m i c i n s t a b i l i t y, l i f e -t h r e a t e n i n g dysrhythmias, inability to protect upper airways, excessive airway secretions, drowsiness, uncooperative behaviour, facial deformity, allergy or hypersensitivity to mask material, pneumothorax, congestive cardiac failure or pneumonia, and those with "do not intubate" status. We diagnosed the pre-existing COPD condition based either on existing medical records and pulmonary function tests, or a compatible history, physical examination and chest radiography, and diagnosed an acute exacerbation in the presence of increased dyspnoea, sputum volume and/or sputum purulence, without any new infiltrate on chest radiography. 
Pre-implementation
Prior to the NIV program, patients who fitted to the above criteria were transferred to the ICU for NIV. The delay in commencing NIV was contributed by the time taken to arrange for ICU admissions and transportation. Furthermore, due to the lack of protocol, inadequate medical therapy and omissions of blood gas measurements were frequently observed, resulting in ill patients being admitted to the floor. Respiratory physicians would then transfer these patients to the medical ICU for NIV should acute hypercapnic respirator y failure persist despite conventional measures.
NIV program and post-implementation
On 1st July 2003 we instituted an education program for ED staff and developed a protocol for ED physicians to commence NIV in the ED. The protocol emphasized on adequate initial medical therapy and mandatory arterial blood gas (ABG) assessments. NIV was commenced only when patients had persistent ac ut e hy perca pn ic res pir at or y fa ilu re d es pite conventional measures, which included two to three repeated inhalations of salbutamol and ipratropium from a wet nebuliser (Hudson, Temecula AC, USA) over 20 to 30 minutes, oxygen supplementation to keep the oxygen saturation of 92-95% via pulse oximetry, and intravenous corticosteroids. For each patient, a dedicated nurse was assigned to assist in the set up and monitoring of patients. Patients were later transferred to the ICU when they were deemed to be clinically stable by the ED physicians. We introduced the protocol gradually; initially during office hours when the intensivists and respiratory therapists were available. After six months, the protocol was implemented throughout the day.
Administration of NIV
In both phases, we used BiPAP Vision (Respironics, Murrysville, PA., USA) in the spontaneous/timed mode. The initial inspiratory airway pressure (IPAP) was started at +18 cm H 2 O and increased by 2 cm increments to a maximum of 24 cm H 2 O, depending on patients' tolerance. The expiratory airway pressure (EPAP) was set at +4 cm H 2 O and minimum respiratory rate at 18 breaths per minute. The fraction of inspired oxygen (FiO 2 ) was adjusted to keep oxygen saturation at 92-95% on pulse oximetry. We used three oronasal masks: Spectrum Disposable Full Face Mask, Spectrum Reusable Full Face Mask or Total Face Mask (all from Respironics). Clinical evaluation and ABG measurements were performed 30-60 minutes after commencement of NIV to ascertain response. We applied NIV initially for at least 6 hours, lengthening this period according to the patients' tolerance. We recommended ETI and invasive mechanical ventilation for respiratory arrest, respiratory pauses with loss of alertness or gasping, psychomotor agitation requiring sedation, worsening or no improvement in pH despite the maximum setting that was tolerable, as well as development of exclusion criteria for NIV. Ultimately, clinical judgment was applied in the decision for ETI.
Data collection
From the registry, we obtained basic demographics, physiologic variables (respiratory rate, heart rate, systolic blood pressure) and ABG measurements pre and post NIV. We also determined the door-to-NIV time, which was defined as the time lag between arrival in the ED to the commencement of NIV. We reviewed each patient's chart to ascertain the Acute Physiology and Chronic Health Evaluation (APACHE) II scores as well as the clinical outcome measures.
Outcome measures
The primary outcome measure was all-cause hospital mortality. The secondar y outcomes we studied included the need for ETI, length of stay in the ICU and total length of hospital stay.
Statistical analysis
We used SPSS statistical software package (version 15.0; SPSS Inc, Chicago, IL, USA). We expressed nominal variables as frequencies and compared groups using the chi-square test and Fisher's exact test. For continuous variables, we presented mean  standard deviation (SD) for parametric data and median (interquartile range [IQR]) for non-parametric data. We compared parametric data using the t test, and non-parametric data using the Mann-Whitney U test. To identify factors predictive of hospital mortality, we first performed a univariate analysis to compare survivors with non-survivors. We entered variables with p-value less than 0.10 into a forward stepwise logistic regression analysis using entry level of 0.05 and removal level of 0.10. We calculated the adjusted odds ratio (OR) with 95% confidence inter val (CI) for independent predictors of hospital mortality. The variables included in the model were age, APACHE II score, respiratory rate and systolic blood pressure at baseline and site of NIV. We considered a p-value of less than 0.05 as significant.
Results

A total of
Pre-implementation, 34 patients received NIV in ICU, while post-implementation, 119 patients received NIV in the ED (Table 1) . Patients in both phases exhibited similar baseline APACHE II score, pre-NIV ABG values and clinical parameters such as heart rate and blood pressure. Following NIV treatment, patients in both phases showed improvement in pH and pCO 2 . In the pre-implementation phase, 15 patients (44%) were transferred to the acute inpatient medical ward from the ED, only to be subsequently transferred to ICU. Among these, 7 patients did not have ABG assessment in the ED and another 6 patients were already acidaemic while in the ED.
The median door-to-NIV time was 3 hours shorter in the post-implementation phase (p<0.001). In the 9 years of the study, there was a reduction in the median door-to-NIV time (Figure 1 ). The median was 70 minutes (IQR 30-114) in the latter half of the study. The hospital mortality rate was lower in the postimplementation phase (1.7% versus 11.8%) compared to the pre-implementation phase (Table 2) . Among pat ients who were a dmitt ed to the f loor and subsequently admitted to the ICU in the preimplementation phase, there was only one mortality. 
Discussion
This study showed that an NIV program in the ED was feasible and could contribute to better clinical o u t c o m e s f o r C O P D p a t i e n t s w i t h s e v e r e exacerbations. We showed a considerable improvement in the mortality rate (11.8 to 1.7%) and halved the length of ICU and hospital stay in the postimplementation phase. While ETI rate did not show any statistical difference, there was a trend towards reduction from 21% to 13%, likely due to the small sample size Today, NIV programs exist in many EDs across the world. In a survey by Hess et al of 132 academic EDs in the United States, NIV was used one or more times per week in 92% of EDs. 13 Sixty-seven percent of EDs in the United Kingdom, 14 and 46% in the European countries use NIV. 15, 16 Ironically, randomised controlled studies (RCT) on this field were often performed in ICU, [17] [18] [19] and little evidence existed to support early NIV in EDs. Fewer than a handful of observational studies have suggested relatively high success rates of NIV in EDs, and these studies were limited by heterogeneous populations that included small samples of patients with COPD. 20, 21 Indeed, earlier initiation of NIV in the ED as opposed to the ICU should theoretically result in outcome benefits, yet Wood et al found in a RCT that NIV in the ED could paradoxically delay ETI and contribute to mortality. 22 There was, unfor tunately, unequal randomisation in this study and only six out of 27 patients had COPD. Our findings now provide some evidence to advocate early use of NIV through protocol-driven assessment of severity and indication of NIV. The main factor in the improvement of clinical outcomes could be the decrease in door-to-NIV time. Two audits from the United Kingdom (UK) 3, 4 revealed that only one-third of patients, already acidotic on admission, were given NIV and only 37% received NIV within an hour. Our experience concurs that in the real world, patients are only recognised when they are severely ill, more so than in RCTs, hence the time to NIV is a critical factor in failure versus success. We have demonstrated that 70 minutes of median doorto-NIV time is achievable and sustainable. This period could provide ample time for administration of standard medical therapy, bedside investigations; namely chest radiography and ABG-and more importantly, discussion or reiteration of resuscitation status. Another contributory factor could be the enhanced awareness of COPD management via our protocol-driven program. The streamlined management could lead to consistent delivery of pre-NIV medical treatment and evaluation of the blood gas status, hence preventing inadvertent admission of unstable patients to the floor which would otherwise have prolonged the door-to-NIV time.
"Real life" studies have shown that the positive impact of NIV on patient outcomes seen under experimental conditions could not be easily translated to the real world, however, our experience suggests otherwise. Girou et al, in a French study of secular trends over 8 years, found that the increased use of NIV for COPD in the ICU was associated with sustained reduction in mortality. 23 By contrast, Price et al, in a national audit of COPD exacerbations in the UK, failed to detect a significant impact of NIV utilisation on mortality. 24 Yet, the overall hospital mortality rate of 3.9% in our study was lower than other "real-life studies" such as a large UK study of 233 hospitals (26%) and a study of NIV administration in the ward (32%). 3, 6 As for failure rate, the literature quoted 15-28% for patients with mild to moderate respiratory acidosis (pH 7.25-7.35) 1, 25 but the rate increased to 62% in severe acidosis (pH <7.25). 26, 27 Our study demonstrated a lower failure rate in both phases with a comparable pH to the studies m e n t i o n e d , w h i c h f u r t h e r d e c r e a s e d p o s timplementation.
We noted a higher respiratory rate in patients from the ICU group, which showed bigger improvement on commencement of NIV compared to the ED group; however, this variable was not a predictor of hospital mortality. It is possible that the delay in NIV commencement could have worsened the patients' clinical condition despite a similar degree of respiratory acidosis, and hence the relationship between time of NIV commencement and the respiratory rate could be explored further in prospective studies. The APACHE II score which indicates the severity of illness was expectedly a predictor of hospital mortality, and consistent with previous findings. 11, 28 Our experience indicated that the ED could be an appropriate location for early NIV. Most EDs have dedicated intensive monitoring area which could provide up to 1:1 nurse to patient ratio for NIV delivery. 8 Emergency physicians and nurses could acquire the knowledge and skills to administer NIV safely and effectively. These skills, usually confined to the realm of respiratory therapists and intensivists, were key components to the success of our NIV program. Other success attributes included the gradual introduction of the program as well regular feedback and continual education to ensure knowledge retention. Finally, we did not underestimate the influence of staff 'buy in' as an essential factor.
The limitation of our study was the possible learning effect that could have explained the outcomes. It could be argued that as familiarity with the technique grew with time, the mortality would have expected to decrease in the post-implementation group as suggested by Carlucci et al. 5 However, it would be unlikely that the temporal trend could be the prevailing factor due to the precipitous drop in mortality observed in the This implied that familiarity might not entirely explain the change in outcomes. Another limitation was that we did not have the number of COPD patients attending the emergency department who met the inclusion criteria but did not receive NIV in the entire duration of the study. However, we performed regular audits and found that more than 95% of patients who were eligible for NIV did receive NIV. Lastly, our study was also limited by the small sample size of our study and the low number of deaths.
Conclusions
In summary, early NIV in the ED, coupled with a program that included staff training and clear protocols on patient selection, results in better hospital outcomes in patients with severe COPD exacerbations. Importantly, our study also shows that such a program is sustainable.
